PAIN RELIEF INNOVATION
South Rampart Pharma, Inc. is a clinical-stage life science company focused on advancing innovative small molecules designed to overcome the risks of current pain medicines.
Learn More

Our novel, non-addictive lead asset is designed to avoid the liver and kidney toxicities of currently available pain medicines.

Lead Program SRP-001 avoids liver toxicity of acetaminophen.

SRP-001 is currently in a Phase 1 clinical trial evaluating safety, tolerability, and pharmacokinetics.

News and Milestones


  • South Rampart Pharma publishes SRP-001 in Scientific Reports
  • LEARN MORE

  • South Rampart Pharma: Phase 1 Success and Expanded Phase 2 for Neuropathic and Acute Pain
  • LEARN MORE

  • South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain
  • LEARN MORE


  • South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program
  • LEARN MORE


  • Co-founder & CEO, Dr. Hernan Bazan, speaks with Dr. Moira Gunn in NPR's Tech Nation Radio about the need for pain relief innovation
  • LEARN MORE

  • Biotechnology Innovation Organization – I am BIO Podcast
    Episode 80: Cracking the Code on Pain Relief
  • LEARN MORE

OUR MISSION TO ADVANCE THE SAFE TREATMENT OF PAIN

Technology

Characterizing and carefully modeling the body’s metabolic pathways facilitated development of a novel molecule designed to avoid limitations of current non-opioid analgesics.

Pipeline

Our pipeline contains compounds designed to effectively treat pain and fever across a range of clinical indications, clinical settings, and dose forms.

Global Need

Patients and the healthcare systems that care for them need an alternative to addictive or potentially toxic pain medications and the heavy downstream costs they incur.